Journal Article

Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma

Samimi, Mahtab

2019

Overview

Merkel cell carcinoma (MCC) is an aggressive skin cancer. Until 2017, patients with advanced disease were typically treated with conventional chemotherapies, with a median response duration of 3 months. Increased evidence of the role of the immune system in controlling this cancer has paved the way for immune-based therapies, with programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitors at the frontline. Avelumab, an anti-PD-L1 antibody, was the first-ever drug approved in advanced MCC after showing meaningful efficacy in a second-line setting. Objective responses were observed in one-third of patients and, most importantly, were durable with half of patients and one-third of patients still alive at 1 and 2 years, respectively. When used in a first-line setting, PD-1/PD-L1 inhibitors (avelumab, pembrolizumab, nivolumab) are even more promising as objective responses are observed in approximately 50–70% of patients within the first 4–8 weeks of treatment. Safety profiles are acceptable with 10–20% of patients experiencing adverse events grade ≥ 3. PD-1/PD-L1 inhibitors are considered the standard of care in advanced MCC and are currently being investigated in the adjuvant and neoadjuvant settings. However, innovative treatments are still needed in the metastatic setting, as approximately 50% of these patients will not persistently respond to currently available immunotherapies, and no predictors of response are available yet. Therefore, other immunotherapeutic strategies are now being investigated—ideally in combinations—to enhance the various aspects of the immune response against tumoral cells.

• Publisher: Springer International Publishing,Springer Nature B.V,Springer Verlag
• Subject: Adenosine / Antigens / Apoptosis / Biopsy / Cancer / Cancer therapies / Cell cycle / Cytokines / Dermatology / Genomes / Human health and pathology / Hypotheses / Immune checkpoint inhibitors / Immune system / Immunotherapy / Life Sciences / Lymphatic system / Medical prognosis / Medicine / Medicine & Public Health / Metastasis / Monoclonal antibodies / Mutation / Pathogenesis / Pharmacology/Toxicology / Pharmacotherapy / Review Article / Skin cancer / Targeted cancer therapy / Tumors